Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate Cardiovascular Outcomes During Treatment With Lixisenatide in Type 2 Diabetic Patients After an Acute Coronary Syndrome

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate Cardiovascular Outcomes During Treatment With Lixisenatide in Type 2 Diabetic Patients After an Acute Coronary Syndrome

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 15 Jul 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lixisenatide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Biomarker; Registrational
  • Acronyms ELIXA
  • Sponsors Sanofi
  • Most Recent Events

    • 11 Jul 2022 Results (n=4957) of a biomarker analysis assessing protein biomarkers in people with type 2 diabetes at high risk of cardiovascular outcomes and death published in the Diabetes Care
    • 07 Jun 2022 Results (n=4957) presented at the 82nd Annual Scientific Sessions of the American Diabetes Association
    • 16 Jun 2020 Results assessing Impact of Blood Pressure on Risk of Death and its Influence by Prior Cardiovascular Disease in Patients with Type 2 Diabetes presented at the 80th Annual Scientific Sessions of the American Diabetes Association
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top